Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Blue Monday originated from a publicity stunt, but seasonal affective disorder is a real affliction that affects millions of ...

Inauguration Day in photos, the allure of coffee shops, how to handle seasonal depression: Catch up on the day’s stories ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

Higher daily step counts were linked to fewer depressive symptoms and a lower risk for depression in a new meta-analysis.

Rebutting the serotonin theory of depression exposed an important gap in our knowledge. But Joanna Moncrieff's new book ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...